Other Information
−Removed: During the fiscal quarter ended March 31, 2024, none of the Company’s
−Removed: directors or officers adopted , modified , or terminated a Rule 10b5-1 trading arrangement, or a non-Rule 10b5-1 trading arrangement, in
−Removed: each case as defined in Item 408 of Regulation S-K.
+Added: the quarter ended June 30, 2024, none of the Company’s directors or officers adopted , modified , or terminated a
+Added: Rule 10b5-1 trading arrangement, or a non-Rule 10b5-1 trading arrangement, in each case as defined in Item 408 of Regulation S-K.
+Added: First Amendment to the Bylaws of INmune Bio Inc.
Rule 13a-14(a)/ 15d-14(a) Certification of Chief Executive Officer*
13 unchanged sentences
INmune Bio Inc.
+Added: August 1, 2024
/s/ Raymond J.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 1, 2024
Chief Financial Officer, Treasurer, Secretary
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.